Leukapheresis Devices Market to Surpass US$ 37.40 Million by 2027 - Coherent Market Insights

Global Leukapheresis Market, by Device Type (Apheresis Devices, Leukapheresis Columns & Cell Separators, Leukoreduction Filters, and Leukapheresis Disposables), By Application (Research Applications and Therapeutic Applications), by End User (Hospitals, Academic and Research Institutes, Pharmaceutical and Biotechnology Companies, and Blood Component Providers and Blood Centers), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 22.32 million in 2020 and is expected to exhibit a CAGR of 7.6% during the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.

The increasing initiatives taken by key players in the field of leukapheresis is a major factor that is expected to drive growth of the leukapheresis devices market during the forecast period. For instance, in May 2017, a leading medical devices company, Fresenius (Germany), announced its expanded production of medical devices in Haina, Dominican Republic (U.S.). The Haina plant manufactures and exports apheresis systems for plasma and platelet collection as well as medical devices for blood separation.

Furthermore, in January 2018, MedAware Systems, Inc. launched a comprehensive database on apheresis through its SOHInfo division, carrying data from clinical trials, cohort studies, medical journals, and others.

Leukapheresis Devices Market - Impact of Coronavirus (Covid-19) Pandemic

The coronavirus (COVID 19) pandemic and lockdowns in various countries across the globe have impacted the financial status of business across all the sectors. The private healthcare sector is one the sectors which has been majorly impacted by the COVID-19 pandemic.

The lockdown in various countries due to the COVID-19 pandemic has created an economic burden on the private healthcare sectors. Healthcare providers were facing challenges with regards to manpower, equipment, consumables, and other resources to ensure safety in treatment of patients with other diseases, and declining outpatients visits, etc.

Thus, COVID-19 pandemic has affected the economy in three main ways; 1) by directly affecting the production and demand; 2) by creating disruptions in distribution channels; and 3) through its financial impact on companies and financial markets

Thus, impact of the coronavirus (COVID-19) pandemic is expected to limit growth of the global leukapheresis devices market during the forecast period

Browse 35 Market Data Tables and 32 Figures spread through 155 Pages and in-depth TOC on Leukapheresis Devices Market, by Device Type (Apheresis Devices, Leukapheresis Columns & Cell Separators, Leukoreduction Filters, and Leukapheresis Disposables), By Application (Research Applications and Therapeutic Applications), by End User (Hospitals, Academic and Research Institutes, Pharmaceutical and Biotechnology Companies, and Blood Component Providers and Blood Centers), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Forecast to 2027"

To know the latest trends and insights related to leukapheresis devices market, click the link below:

https://www.coherentmarketinsights.com/market-insight/leukapheresis-devices-market-4142

Key Takeaways of the Leukapheresis Devices Market:

• The global leukapheresis devices market is expected to exhibit a CAGR of 7.6% during the forecast period (2020-2027), owing to increasing initiatives taken by key players in the field of leukapheresis
• Among device type, the Apheresis Devices segment is expected to hold a major revenue share in 2027. An apheresis device, which receives blood removed from a patient or donor’s body and separates it into its various components: plasma, platelets, white blood cells, and red blood cells.
• Major players operating in the global leukapheresis devices market include Asahi Kasei Medical Co. Ltd., Haemonetics Corporation, Terumo BCT Inc., STEMCELL Technologies Inc., Fresenius SE & Co. KGaA, BioIVT, Grifols, S.A, and Key Biologics, LLC